- New DSI Flagstaff facility offers upscale patient amenities in a beautiful setting

- Open House event on June 7 and 8, 2012 welcomes patients, physicians and public

FLAGSTAFF, Ariz., June 7, 2012 /PRNewswire/ -- DSI Renal, a leading provider of dialysis services for patients suffering from chronic kidney failure, today announced the opening of its DSI Flagstaff Dialysis facility.  The new clinic, located on Walgreens Street with convenient interstate access, diversifies the Flagstaff dialysis market, which previously was home to only one dialysis facility.  DSI Flagstaff Dialysis will host an Open House event on Thursday, June 7 and Friday, June 8from noon to 8 pm on both days for patients, physicians and other visitors interested in seeing the new facility.

"We are extremely pleased to open the doors of this impressive new location, which offers a number of upscale amenities for patients," said Harnath Singh, MD, Medical Director at DSI Flagstaff Dialysis.  "Our clinic offers exceptional dialysis care and state-of-the-art medical information systems in an inviting and beautiful setting."

The new clinic, located 2268 N. Walgreens St., offers dialysis patients heated massage chairs, individual station flat-screen TVs, flexible scheduling and plenty of free, private parking.  DSI Flagstaff also offers peritoneal dialysis training for in-home treatment and maximum patient convenience.

"DSI is pleased to be offering Flagstaff residents a new choice for meeting their dialysis needs," said Jason Gunter, Executive Vice President & Chief Operating Officer at DSI Renal.  "We look forward to working with Dr. Singh and the talented clinic staff to serve these patients and exceed their expectations."

Existing and prospective patients, physicians, media and the public are encouraged to attend the DSI Flagstaff Dialysis Open House, which will be held June 7 and 8 from 12:00 pm to 8:00 pm MT both days.  The Open House festivities will kick off with a ribbon cutting ceremony at noon on June 7^th.  No RSVP is necessary.

About DSI Renal

DSI Renal (formed as Dialysis Newco, Inc.) is a leading provider of dialysis services in the United States, offering state-of-the-art treatment for patients suffering from chronic kidney failure and renal disease.  Together with its physician partners, DSI Renal owns and operates 85 dialysis clinics in 23 states.  The company plans for growth through acquisition and development of new clinics as well as through establishment of additional joint venture partnerships with leading nephrologists for the clinic, hospital and alternate settings.  For more information, please visit www.dsi-corp.com.

Clinic Contact:
Kim Meehl
DSI Flagstaff Dialysis
(928) 556-5500
Admissions: (888) 287-9312

Corporate Contact:
Giles Ward
DSI Renal
(615) 777-8200
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Media Contact:
Angela Novak
Corner Office Communications
(615) 406-0715
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

SOURCE DSI Renal

RELATED LINKS
http://www.dsi-corp.com.

...

PARIS— Patients starting dialysis after primary renal transplant failure who are waitlisted for repeat transplantation have a higher risk of dying over the first three years after graft loss than dialysis patients waitlisted for their first transplant, investigators reported at the 49^th Congress of the European Renal Association-European Dialysis and Transplant Association .

Lynsey Webb, MD, a clinical research fellow at the U.K. Renal Registry at Southmead Hospital in Bristol, and co-workers determined survival after transplant failure only in patients deemed suitable for repeat transplantation.

The analysis included 1,498 patients starting hemodialysis (HD) or peritoneal dialysis (PD) after failure of a first renal transplant and who were waitlisted for repeat transplantation within two years of graft failure and 11,412 patients starting HD or PD as their initial form of renal replacement therapy (RRT) who were waitlisted for transplantation within two years of starting RRT. Patient data were obtained from the U.K. Renal Registry database from 2000-2008.

Patients with established renal failure (ERF) who undergo successful renal transplantation have improved survival and quality of life compared with patients who remain on dialysis, Dr. Webb said. Patients starting dialysis after graft failure have increased mortality compared with dialysis patients waitlisted for primary renal transplantation because patients with failed transplants have had ERF for a significantly longer period and are thus likely to have more comorbidities.

Dr. Webb emphasized that the U.K. Renal Registry does not collect annual co-morbidity data and thus cannot adjust for the effect of the accrued co-morbidity in failed transplant recipients. Thus, the analysis included only failed transplant recipients who were deemed “fit enough” to be listed for re-transplantation when comparing survival with waitlisted incident dialysis patients. Patients with failed grafts who are listed for a second transplantation are likely to have fewer comorbidities than failed transplant recipients not fit for wait listing (for example, due to cardiovascular disease, infection, or malignancy) and, therefore, are arguably a more appropriate comparator group, she said.

Results showed that in the first year following graft loss, re-listed patients were 1.6 times more likely to die than dialysis patients awaiting their first transplant. This increased risk persisted over the first three years.

“This study suggests that patients with failing transplants need to be reviewed regularly with timely planning for their return to dialysis,” Dr. Webb said.  “Careful consideration should be given to timely waitlisting for repeat transplantation, the hope being prompt waitlisting prior to dialysis commencement would minimize any time on dialysis.”

Dr. Webb acknowledged that missing co-morbidity data may represent a possible study limitation. She also said that studies are needed to examine the causes of mortality and morbidity after graft failure.

“We are planning to look at the cause of death (as recorded on official death certificates) to explore what specifically these patients die from. For example, is it cardiovascular disease or infection?  This will allow more targeted health screening and surveillance.”

...